This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
HOLLISTON, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of tools to advance life science research and regenerative medicine, announces that the "InBreath" tracheal scaffold and bioreactor system manufactured by Harvard Apparatus Regenerative Technology, Inc. (HART), its wholly owned regenerative medicine technology subsidiary, were used in the first successful transplant of a regenerated trachea in the United States. The recipient of the implant, two-year-old Hannah Genevieve Warren, is recovering at Children's Hospital of Illinois, where the surgery was performed on April 9, 2013. The surgery was also the world's first successful pediatric regenerated trachea transplant using a synthetic scaffold.
The "InBreath" tracheal scaffold made for two-year-old Hannah Warren. (C) Harvard Apparatus Regenerative Technology.
The "InBreath" bioreactor used to create the regenerated trachea for Hannah Warren. (C) Harvard Apparatus Regenerative Technology.
Photos accompanying this release are available at
Hannah was born on August 22, 2010 in Seoul, South Korea with tracheal agenesis (lack of a trachea), and was only able to breathe through a tube inserted in her esophagus that connected to her lungs. Tracheal agenesis is 100 percent fatal, and no child born with the condition has ever lived beyond six years. Hannah had lived in the intensive care unit for two and a half years at Seoul National Hospital before being transported to Illinois for the surgery.